Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on January 6, 2011, at a price of £12.50 per share. These acquisitions were executed through the Company's Share Reward Plan, specifically under the Dividend Reinvestment element. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 6, 2011.
- Share Price: £12.50 per Ordinary share.
- Transaction Type: Acquisitions via the Dividend Reinvestment element of the Share Reward Plan.
- Participants: Nine individuals, including Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. S A Hussain, Dr. D Pulman, Mr. D S Redfern, Ms. C Thomas, and Mr. P J T Vallance.
- Share Counts: Most participants acquired 29 shares; Mr. Hussain acquired 7, Dr. Pulman acquired 11, and Mr. Vallance acquired 13.